Improving cancer therapy by identification of novel drug leads modulating transcription termination bridging molecular biology and therapeutic applications

Our value proposition is improving cancer therapy by identification of novel anti-cancer candidate drug leads modulating transcription termination, bridging molecular cancer biology and therapeutic applications.We have developed a methodology to directly measure alterations in transcription termination and successfully subjected it to miniaturization and automatization processes. We are applying for funding to validate a screening platform to identify small molecule inhibitors of transcription termination.